As these smaller tumors in Figure 4B showed a more uniform response to the CAIR minus anti-CD40 regimen, we asked whether the locally administered components of this regimen (the RT and the IT-CpG and IT-IC) needed to be delivered directly to the small tumor to have this potent anti-tumor effect. The gene discussed is CD40; the disease is neoplasm.